Genetic Variants Associated With Cancer Therapy–Induced Cardiomyopathy
Authors: Pablo Garcia-Pavia, Yuri Kim, Maria Alejandra Restrepo-Cordoba, Ida G. Lunde, Hiroko Wakimoto, Amanda M. Smith, Christopher N. Toepfer, Kelly Getz, Joshua Gorham, Parth Patel, Kaoru Ito, Jonathan A. Willcox, Zoltan Arany, Jian Li, Anjali T. Owens, Risha Govind, Beatriz Nuñez, Erica Mazaika, Antoni Bayes-Genis, Roddy Walsh, Brian Finkelman, Josep Lupon, Nicola Whiffin, Isabel Serrano, William Midwinter, Alicja Wilk, Alfredo Bardaji, Nathan Ingold, Rachel Buchan, Upasana Tayal, Domingo A. Pascual-Figal, Antonio de Marvao, Mian Ahmad, Jose Manuel Garcia-Pinilla, Antonis Pantazis, Fernando Dominguez, A. John Baksi, Declan P. O’Regan, Stuart D. Rosen, Sanjay K. Prasad, Enrique Lara-Pezzi, Mariano Provencio, Alexander R. Lyon, Luis Alonso-Pulpon, Stuart A. Cook, Steven R. DePalma, Paul J.R. Barton, Richard Aplenc, Jonathan G. Seidman, Bonnie Ky, James S. Ware, Christine E. Seidman
Journal: Circulation (2019)

Background: Cancer therapy–induced cardiomyopathy (CCM) is associated with cumulative drug exposures and preexisting cardiovascular disorders. These parameters incompletely account for substantial interindividual susceptibility to CCM. We hypothesized that rare variants in cardiomyopathy genes contribute to CCM. Methods: We studied 213 patients with CCM from 3 cohorts: retrospectively recruited adults with diverse cancers (n=99), prospectively phenotyped adults with breast cancer (n=73), and prospectively phenotyped children with acute myeloid leukemia (n=41). Cardiomyopathy genes, including 9 prespecified genes, were sequenced. The prevalence of rare variants was compared between CCM cohorts and The Cancer Genome Atlas participants (n=2053), healthy volunteers (n=445), and an ancestry-matched reference population. Clinical characteristics and outcomes were assessed and stratified by genotypes. A prevalent CCM genotype was modeled in anthracycline-treated mice. Results: CCM was diagnosed 0.4 to 9 years after chemotherapy; 90% of these patients received anthracyclines. Adult patients with CCM had cardiovascular risk factors similar to the US population. Among 9 prioritized genes, patients with CCM had more rare protein-altering variants than comparative cohorts ( P ≤1.98e–04). Titin-truncating variants (TTNtvs) predominated, occurring in 7.5% of patients with CCM versus 1.1% of The Cancer Genome Atlas participants ( P =7.36e–08), 0.7% of healthy volunteers ( P =3.42e–06), and 0.6% of the reference population ( P =5.87e–14). Adult patients who had CCM with TTNtvs experienced more heart failure and atrial fibrillation ( P =0.003) and impaired myocardial recovery ( P =0.03) than those without. Consistent with human data, anthracycline-treated TTNtv mice and isolated TTNtv cardiomyocytes showed sustained contractile dysfunction unlike wild-type ( P =0.0004 and P &lt;0.002, respectively). Conclusions: Unrecognized rare variants in cardiomyopathy-associated genes, particularly TTNtvs, increased the risk for CCM in children and adults, and adverse cardiac events in adults. Genotype, along with cumulative chemotherapy dosage and traditional cardiovascular risk factors, improves the identification of patients who have cancer at highest risk for CCM. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifiers: NCT01173341; AAML1031; NCT01371981.